echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cancer Cell: The team of Shen Hongbing and Hu Zhibin of Southern Medical University reveals a new genetic mechanism of lung cancer pathogenic variation

    Cancer Cell: The team of Shen Hongbing and Hu Zhibin of Southern Medical University reveals a new genetic mechanism of lung cancer pathogenic variation

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Lung cancer is the malignant tumor


    On September 15, 2022, the team of Shen Hongbing of Nanjing Medical University and the team of Hu Zhibin collaborated to publish a research paper


    GWAS policy limitations

    Academician Shen Hongbing of Nanjing Medical University and Professor Hu Zhibin's team carried out a number of non-small cell lung cancer GWAS in the Chinese group, identified more than 20 genetic variants associated with the onset of NSCLC, and partially revealed the genetic mechanism of lung cancer onset, however, the traditional GWAS strategy based on chip filling still has certain limitations


    On the one hand, the chip covers only a subset of genomic variants, and its inference of genotypes of other genomes relies on filling techniques, so accuracy relies on population-matched and more comprehensive and accurate haplotype reference databases, and over the past two decades, genome-wide association studies have strongly linked


    On the other hand, the chip filling strategy is only suitable for studying common and low-frequency variants, and the analytical ability of rare pathogenic variants is insufficient


    A complete picture of lung cancer pathogenic and rare pathogenic variant genes in the Chinese population

    Nanjing Medical University researchers performed large-scale whole-genome sequencing


    To study common and low-frequency variations, they first constructed a high-resolution NJLCC haplotype reference panel containing WGS data


    Not only that, for the rare loss-of-function variant, the researchers identified BRCA2 and 18 other cancer-susceptibility genes that affected 5.


    In addition, the researchers found that the promoter variant of BRCA2 also had a significant effect on NSCLC risk, with a prevalence comparable


    Research implications

    The researchers conducted in-depth whole genome sequencing of 2984 NSCLC cases and 3020 health-controlled peripheral blood samples, and carried out the largest WGS-based genomics association study


    The team of Nanjing Medical University applied large-scale WGS to the genome-wide association study of NSCLC for the first time, constructed a high-quality Chinese group haplotype reference library, newly discovered multiple common and low-frequency susceptibility variants associated with NSCLC, and systematically resolved the rare pathogenic variants in the coding region and regulatory region of NSCLC.


    Resources:

    This article is intended to introduce medical research advances and cannot be used as a reference for


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.